



General Assembly

January Session, 2013

Committee Bill No. 465

LCO No. 2957



Referred to Committee on PUBLIC HEALTH

Introduced by:
(PH)

***AN ACT REQUIRING NEWBORN SCREENING FOR
ADRENOLEUKODYSTROPHY.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Subsection (a) of section 19a-55 of the general statutes is
2 repealed and the following is substituted in lieu thereof (*Effective*
3 *October 1, 2013*):

4 (a) The administrative officer or other person in charge of each
5 institution caring for newborn infants shall cause to have administered
6 to every such infant in its care an HIV-related test, as defined in section
7 19a-581, a test for phenylketonuria and other metabolic diseases,
8 hypothyroidism, galactosemia, sickle cell disease, maple syrup urine
9 disease, homocystinuria, biotinidase deficiency, congenital adrenal
10 hyperplasia, adrenoleukodystrophy and such other tests for inborn
11 errors of metabolism as shall be prescribed by the Department of
12 Public Health. The tests shall be administered as soon after birth as is
13 medically appropriate. If the mother has had an HIV-related test
14 pursuant to section 19a-90 or 19a-593, the person responsible for
15 testing under this section may omit an HIV-related test. The
16 Commissioner of Public Health shall (1) administer the newborn

17 screening program, (2) direct persons identified through the screening
18 program to appropriate specialty centers for treatments, consistent
19 with any applicable confidentiality requirements, and (3) set the fees to
20 be charged to institutions to cover all expenses of the comprehensive
21 screening program including testing, tracking and treatment. The fees
22 to be charged pursuant to subdivision (3) of this subsection shall be set
23 at a minimum of fifty-six dollars. The Commissioner of Public Health
24 shall publish a list of all the abnormal conditions for which the
25 department screens newborns under the newborn screening program,
26 which shall include screening for amino acid disorders, organic acid
27 disorders and fatty acid oxidation disorders, including, but not limited
28 to, long-chain 3-hydroxyacyl CoA dehydrogenase (L-CHAD) and
29 medium-chain acyl-CoA dehydrogenase (MCAD).

This act shall take effect as follows and shall amend the following sections:		
Section 1	October 1, 2013	19a-55(a)

PH *Joint Favorable*

APP *Joint Favorable*